Obagi Medical gets higher offer from Merz Pharma

(Reuters) – Neurological and dermatology drugs maker Merz Pharma Group offered to buy cosmetic products maker Obagi Medical Products Inc for $383.5 million, topping a bid by Canada’s Valeant Pharmaceuticals International Inc . Merz’s $22 per share bid represents a premium of 11 percent to Valeant’s offer of $19.75. Obagi shares were trading above Merz’s offer price at $22.90 in premarket trade, suggesting that some investors expect a bidding war. …

Statin side effects can often be overcome: study

By Genevra Pittman NEW YORK (Reuters Health) – Most people who stop taking cholesterol-lowering statins – because of side effects or for another reason – are able to restart the same drug or a similar one without lasting problems, a new study suggests. That’s important because for people who need statins, quitting them for good increases the chance of serious heart problems, researchers said, so doctors and patients should think carefully before letting milder reactions lead them to give up on the drugs altogether. …

1 83 84 85 86 87 88